Our news SATT Lutech

4P-Pharma, a clinical-stage biotechnology company and the research center Institut de la Vision (Sorbonne Université, Inserm, CNRS) establish a partnership agreement for the development of 4P020, a promising therapeutic approach for dry age-related macular degeneration (dAMD) and Stargardt disease with the support of the SATT Lutech. This drug candidate, initially studied by Dr Valerie Fontaine at the Institut de la Vision, opens&hellip

Our partnership (InOSTEO project) with the team of Prof. F.Berenbaum (centre de recherche Saint-Antoine UPMC/INSERM) and SATT Lutech is featured in the SATT Lutech october newsletter.   ET SI TOUT S’ARTICULAIT ! Qu’est-ce qui a motivé 4P-Pharma pour s’engager dans le programme ?    « Tout d’abord, nous sommes ravis de participer au développement du programme InOSTEO.&hellip